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1. Introduction
 
  Non-small cell lung cancer (NSCLC) accounts for 75% 
of the total number of lung cancer. Up to now, excision 
is still the only potential treatment approach for NSCLC 
and has become a “standard therapy” for NSCLC. After 
complete resection, the five-year survival rate is about 
15%[1]. Though the methods for resection have improved 
continually in recent years, for most patients, they have 
been in locally advanced stage or with distant metastasis 
at the time of diagnosis, not suitable for receiving surgical 
treatment, or local and regional lymph node recurrence 
and/or metastasis after surgery. These are all the main 
reasons for therapy failure. Nearly 30% of patients had 
local recurrence and regional lymph node metastasis 
within 5 years after surgery. Even after complete resection, 
there were still a large number of patients dying of tumor 
recurrence and metastasis. A large number of studies and 
meta analysis showed that radiotherapy after surgery could 
improve the local tumor control rate, but did not increase or 
decrease the mortality risk of stage 栿 NSCLC patients[2-4]. 
Therefore, there are some controversies on radiotherapy 
after surgery in clinic. During the period of January 2007 to 
June 2011, our hospital carried out surgery + chemotherapy 
and surgery + chemoradiotherapy respectively for stage 栿
A NSCLC patients with total pneumonectomy or pulmonary 
lobectomy. We have summarized some experience and 
now it is reported as follows with the purpose of providing 
reference for clinical practice.
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Objective: To investigate the effect of chemoradiotherapy after surgery on 栿A stage non-
small cell lung cancer (NSCLC). Methods: A total of 156 NSCLC patients undergoing total 
pneumonectomy or pulmonary lobectomy were included in this study. The chemotherapy group 
(n=75) received the protocol of cisplatin (DDP) + gemcitabine (GEM) / docetaxel (DOC) / vinorelbine 
(NVB); the radiotherapy + chemotherapy group (n=81) received sequential chemoradiotherapy. 
The response rate, local control rate in 1 to 2 years, overall survival (OS), progression-free 
survival (PFS) and adverse reactions were evaluated. Results: The overall response rate was 
obviously higher in radiotherapy + chemotherapy group (79.4%) than in chemotherapy group (56.8%) 
(P敿0.01). The 1 year local control rates for chemotherapy group and radiotherapy + chemotherapy 
group were (69.1±7.9)% and (77.8±8.2)% respectively and the difference reached statistical significance
 (P敿0.001). The 2 year local control rates were (42.1±6.1)% and (61.5±6.9)% respectively (P敿0.001). 
The difference in median follow-up time between the two groups did not reach statistical 
meaning (P斁0.05), while the median PFS of two groups were 10.8 months and 16.9 months 
respectively (P敿0.001). 1-year and 3-year survival rates were obviously higher in radiotherapy 
+ chemotherapy group than in chemotherapy group, and the difference reached statistical 
significance (P敿0.05 or P敿0.01). The adverse reactions manifested as hematological toxicity and 
digestive tract reaction in the two groups. In the radiotherapy + chemotherapy group, incidences 
of radiation-induced esophagus injury and lung injury were 24.7% and 34.6% respectively, all 
occurring within 2 to 6 weeks after the start of radiation and both below grade 2. Conclusions: 
Chemoradiotherapy after surgery can improve local control rate and reduce or prevent distant 
metastasis, but there are still many controversies. In clinical work, we should carefully evaluate 
each patient’s age, lung function, basic physical condition scoring and complications to choose a 
therapeutic schedule that is suitable for the patient.
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2. Materials and methods
2.1.  Enrolled patients
   9The study enrolled 156 stage 栿A NSCLC patients treated 
at the department of thoracic surgery of our hospital with 
complete follow-up data during the period of January 2007 
to June 2011. All the patients were diagnosed as having 
NSCLC pathologically, and received total pneumonectomy 
or pulmonary lobectomy. Before treatment, Chest CT, 
abdomen CT, cranial MRI, bone ECT and other checks were 
carried out to exclude distant metastasis; routine blood 
tests, biochemical examination and electrocardiography 
were carried out o exclude chemotherapy contraindications. 
Eastern Cooperative Oncology Group performance status 
scoring was 0-1 and predicted lifetime >12 weeks. The 
hospital’s ethics committee approved all the study methods 
and all the enrolled patients had signed informed consent 
form.
2.2. Grouping methods
   One hundred and fifty-six patients were divided into 
chemotherapy group and radiotherapy + chemotherapy group 
according to treatment methods after operation. The clinical 
characteristics of the two groups were shown in Table 1. 
There was no statistical difference in clinical characteristics 
between the two groups (P>0.05).
Table 1 







Gender   Male 52   54
    Female 23   27
Age (years) Range 42-75 45-72
  Median 65   68
ECOG performance 
status scoring
0 19   22
1 56   59
Histology Adenocarcinoma 39   37
    Squamous 
cellcarcinoma
26   27
    Adenosquamous 
carcinoma
 8   12
    Others  2    5
Location    Center 23   26
    Periphery 52   55
T stage T1  9    8
T2 41   46
T3 25   27
N stage N1 12  14
N2 63   67
Surgical modality   Total pneumonectomy 29   31
    Pulmonary lobectomy 96 100
Chemotherapy 
protocol    
GP  7     9
NP 56   59
DP 12   13
GP = gemcitabine (GEM) + cisplatin (DDP); NP = vinorelbine (NVB) + 
DDP; DP = docetaxel (DOC) + DDP.
2.3. Therapeutic methods
  The chemotherapy group received the protocol of cisplatin 
(DDP) + gemcitabine (GEM)/docetaxel (DOC)/vinorelbine 




   DDP 60-75 mg/m2, used in 2 to 3 days, also combined 
with GEM/DOC/NVB. GP protocol: GEM 800-1 000 mg/(m2.d),
d1, d8; DP protocol: DOC 60-75 mg/m2, d1; NP protocol: 
NVB 20-25 mg/(m2.d), d1, d8. Twenty-eight days was used 
as one chemotherapy cycle. All the patients received 
chemotherapy for 4 cycles. The chemotherapy group 
received chemotherapy after surgery; the radiotherapy + 
chemotherapy group did 2 to 4 chemotherapy cycles, then 
1 cycle of radiotherapy, chemotherapy was continued after 
radiotherapy and 4 treatment cycles would be completed in 
total.
2.3.2. Radiotherapy
   CT scanning range was set from mandible’s lower border to 
the level below the diaphragm, including adrenal gland. The 
target volume included involved area of mediastinal lymph 
node and lymphatic drainage area where the pathology 
was negative after operation, but highly skeptical before 
operation, or lymph node dissection not completely deemed 
by surgery. For the patients whose right middle or left lobe, 
left lower lobe suffered lesion and mediastinal lymph node 
was invaded, subcarinal lymph node was encased in clinical 
target volume (CTV); for left upper lobe, if mediastinal 
lymph node and subcarinal lymph node were invaded, the 
aortic window lymph node would be encased in CTV; for 
the patients whose subcarinal lymph node or mediastinal 
lymph node were invaded, the homolateral hilus of lung 
would be encased in CTV. The planned target volume (PTV) 
was CTV expanded 1.0 cm. The evaluation of radiotherapy 
plans was optimized by dose volume histogram (DVH). 
Pulmonary tissue (V20) was below 25%, the heart tissue (V40) 
was below 45%, while the spinal cord required the maximum 
dose point was below 40 Gy, and the maximum dose point 
of the esophagus was below 60 Gy. It was planned to use 
VARIAN 23EX linear accelerator, 6 MV-X beam irradiation, 
conventional fraction, irradiation dose 2.0 Gy/time, 5 times/
week, total dose 60 Gy[5]. 
2.4. Observed indicators
   Short-term effect: The effects were evaluated after 
treatment in the two groups. According to solid tumor short 
term therapeutic effect evaluation criteria set by WHO, it 
was divided into complete response (CR), partial response 
(PR), stable disease (SD), progressive disease (PD), response 
rate, RR=(CR+PR)/total cases×100%. Long-term effect: 
local control rate in 1 to 2 years: it was evaluated as the 
disappearance of tumor on CT, tumor having residue after 
treatment and the residue was stable or shrinking which 
maintained above 2 month. Overall survival (OS): it was 
calculated from the first time of treatment to the last follow-
up or the death of patient, if the follow-up was lost, it was 
Sheng Chen et al./Asian Pacific Journal of Tropical Medicine (2012)823-827 825
calculated according to the record’s last time; progression-
free survival (PFS): it was calculated from the patients 
beginning to receive treatment to the last follow-up of the 
progressive or non-progressed disease. Adverse reactions 
were evaluated using Radiation Therapy Oncology Group 
(RTOG) criteria. 
2.5. Statistical processing
   All the data were analyzed by SPSS 17.0. The 氈
2 test 
was used for enumeration data and comparison of rates 
between the two groups. The measurement data was 
expressed as mean ± SD, and the t test was adopted for the 
mean comparison. P<0.05 was defined as having statistical 
difference.
3. Results
3.1.  Short-term effects
   As Table 2 shows the overall response rate was 79.4% in 
radiotherapy + chemotherapy group, which was obviously 
higher than that in chemotherapy group (56.8%). The 





Group CR PR SD PD RR
Chemotherapy 13 29 18 15 56.0 (42/75)
Radiotherapy + chemotherapy 29 36 9 7 79.4 (65/81)
3.2. Long-term effect
 
3.2.1. Local control rate  
   One-year local control rates were (69.1±7.9)% and 
(77.8±8.2)% for chemotherapy group and radiotherapy + 
chemotherapy group respectively and the difference had 
statistical significance (t=8.6459, P<0.001). Two-year local 
control rates were (42.1±6.1)% and (61.5±6.9)%, respectively 
(t=23.8599, P<0.001).
3.2.2. OS and PFS
   Follow-up was carried out for all the patients till February 
2012, the follow-up period were 4.2 months to 58.7 months, 
the median follow-up time was 25.6 months. The median OS 
for chemotherapy group and radiotherapy + chemotherapy 
group were 32.2 months and 33.4 months respectively, and 
the difference did not reach statistical significance (P>0.05). 
But the median PFS was 10.8 months and 16.9 months 
respectively in the two groups and the difference had 
statistical significance (t =6.9150, P<0.001).
3.2.3. Survival rate
   As Table 3 shows, 1-year and 3-year survival rates were 
obviously higher in radiotherapy + chemotherapy group than 
in chemotherapy group, and the difference had statistical 
significance (氈
2=5.88, P<0.05, or 氈
2=7.192, P<0.01). While 2 
years rate had no significant difference (氈
2=0.161, P<0.05). 
Table 3  
Survival rate [n(%)].
Group Survival rate
1 year 2 years 3 years
Chemotherapy 58 (77.3) 43 (57.3) 18 (24.0)
Radiotherapy + chemotherapy 74 (91.4) 49 (60.5) 36 (44.4)
3.3. Adverse reactions
   As Figure 1 shows, the adverse reactions manifested as 
hematological toxicity and gastrointestinal reactions in 
the two groups. Hematological toxicities included mainly 
leukopenia and anemia; gastrointestinal reactions included 
mainly nausea and vomiting; hematological toxicity, 
gastrointestinal reactions and incidence of abnormal liver 
function showed no obvious difference between the two 
groups (P>0.05). In the radiotherapy + chemotherapy group, 
incidence of radiation-induced esophageal injury was 
24.7% (20/81) and incidence of radiation-induced lung injury 
was 34.6% (28/81), all occurring within 2 to 6 weeks after the 
start of radiation and both being below grade 2. Imaging 
reexamination was carried out 6 months after the end of 
radiation for radiation-induced lung injury, 22 patients were 
found to have imaging change and the incidence was 27.2%.
Table 4
Adverse reactions.
Toxic and adverse effects
Chemotherapy group
 (n=75)
Radiotherapy + chemotherapy group 
(n=81) 氈
2 P
0 栺 栻 栿 incidence(%) 0 栺 栻 栿 incidence(%)
Leukopenia 29 35   8 3 61.3 29 35 12 5 64.2 0.137 >0.05
Thrombocytopenia 66   7   2 0 12.0 66   9   5 1 18.5 1.271 >0.05
Anemia 54 15   4 2 28.0 57 18 4 2 29.6 0.050 >0.05
Nausea 20 42 10 3 73.3 19 45 15 2 76.5 0.214 >0.05
Vomiting 27 39   7 2 64.0 26 42 10 3 67.9 0.264 >0.05
Abnormal liver function 66   6   3 0 12.0 65 10   6 0 19.8 1.739 >0.05
Radiation-induced lung injury - - - - - 53 22   6 0 34.6 - -
Radiation-induced esophageal 
injury
- - - - - 61 15   5 - 24.7 - -
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4. Discussion
   At present, surgery, chemotherapy and radiotherapy are 
still three major treatment methods for NSCLC, but for most 
patients they have already been in locally advanced stage 
or had distant metastasis at the time of diagnosis, the effect 
of surgery alone for stage 栿A NSCLC is not ideal[6]. The 
main reason is distant or recurrent metastasis. At the time of 
clinical diagnosis, more than 50% of patients are not suitable 
for receiving surgical treatment. Even after complete 
resection of the tumor, there are still a large number of 
patients died of tumor recurrence and metastasis. Patients 
with stage 栿 NSCLC accounts for about 40%, while patients 
with stage 栿A who have potential surgical opportunity are 
few, and most of them are at stage 栿B, who can not tolerate 
surgery[7]. There are still controversies on how to carry out 
treatment, especially for stage 栿A(N2) NSCLC. 
   Previous study[8] revealed that the estimated median 
survival time was 19.3 months with the treatment of F-18-
FDG-PET confined radiotherapy on locally advanced 
NSCLC with concomitant chemotherapy. The radiotherapy 
and chemotherapy after surgery could effectively prolong 
patients’ survival time. Another study[9] revealed that in the 
patients receiving radiotherapy after surgical resection of 
lung cancer invading the aorta or the superior vena cava 
(SVC), the five-year survival rate was 30.7% for the cases with 
aortic invasion and 11% for the ones with SVC involvement. 
The retrospective study of Wu et al[10] suggested that for 
the patients with the stage of N2, the effects of surgical 
treatment alone was not ideal and the five-year survival rate 
was only 20%-25%. Therefore, the radical surgery alone has 
limited benefit. Scholars from home and abroad advocate 
mainly multimodality therapy. At present, it is believed that 
the patients with the stage of N2 or T3-4 N1 after radical 
surgery need to carry out planned clinical study (including 
radiotherapy and chemotherapy). After surgery, as a local 
treatment method, the purpose of radiotherapy is to destroy 
the residual tumor and local subclinical lesions to reduce 
recurrence rate. Three dimensional conformal radiation 
therapy (3-D CRT) can make clear the treatment volume, 
optimize dose distribution, so as to reduce lung and heart’s 
irradiated volume and irradiation dose. The main purpose 
of chemotherapy is to destroy the already happened tiny 
subclinical distant metastasis, or prevent and reduce distant 
metastasis. Therefore, chemoradiotherapy is expected to 
improve the therapeutic effect theoretically. 
   Shen et al[11] explored the effect of “dose-dense” 
pemetrexed plus carboplatin/radiotherapy for locally 
advanced NSCLC, the results showed that thirteen of sixteen 
patients had in field local regional response, and the 
actuarial median OS was 28.6 months in the all patients and 
34.7 months (estimated) in the stage 栿 patients. Uitterhoeve 
et al[12] used concomitant chemoradiotherapy, sequential 
chemoradiotherapy and radiotherapy respectively for the 
treatment of patients with medically inoperable or with 
irresectable NSCLC, the results showed that the 1, 2, and 5 
year actuarial OSs were 46%, 24%, and 15%, respectively. In 
this study, the median OS was 32.2 months and 33.4 months 
respectively in chemotherapy group and radiotherapy 
+ chemotherapy group and the difference reached no 
statistical significance, while the median PFS was 10.8 
months and 16.9 months respectively in the two groups and 
the difference reached statistical significance. The above 
results indicate that chemoradiotherapy after operation 
could prolong PFS and control the progress of the disease 
to a greater extent, but the prolongation of the OS did not 
present obvious improvement, which needs to be confirmed 
by long-term follow-up and increasing sample amount. 
The One-year, 2-year and 3-year survival rates were 77.3%, 
57.3% and 24.0% respectively in chemotherapy group and 
91.4%, 60.5% and 44.4% respectively in the radiotherapy + 
chemotherapy group. The median OS and survival rates were 
similar to those reported by above-mentioned literatures. 
   The adverse reactions of lung cancer radiotherapy 
manifested mainly as radiation-induced lung injury and 
esophageal injury. Though theoretically, 3D-CRT can 
obviously reduce high dose of radiation volume for normal 
lung tissue compared with conventional radiotherapy, the 
radiation-induced lung injury caused by it should not 
be neglected[13,14]. What is different from conventional 
radiotherapy is that we can predict the possibility of 
radiation-induced lung injury according to MLD, V20, 
V30, NTCP and other parameters of lung irradiation dose, 
and a large number of studies on V20, NTCP and others 
are regarded as the prediction parameters for lung injury 
caused by 3D-CRT’s treatment for NSCLC. Different studies 
have different results for their respective relations with 
radiation-induced lung injury. About the factors resulting 
in radiation esophagitis, there are different results from 
different research directions and contents, but the result on 
esophageal maximum dose has been basically confirmed. 
The findings of recurrence and progress of disease are 
different from each other, which included metastasis types 
and incidence[15,16]. Distant metastasis is still the main 
reason for treatment failure of stage 栿A NSCLC or death of 
patients, the next is local recurrence. Patients have already 
had subclinical metastasis at the time of surgery or at the 
time of auxiliary radiotherapy and chemotherapy; The 
chemotherapy has larger limitations; Local radiotherapy 
can not prevent the migration, bloodstream or lymph node 
metastasis, of residual tumor cells; Chemoradiotherapy 
after operation further decreases the body’s immune 
ability, which is suitable for the growth of tumor cells[17]. 
In this study, we were not able to make detailed analysis 
on disease progress in the two groups. In the future, we will 
focus on it, so as to further discuss the long-term effect of 
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radiochemotherapy after operation. 
   In recent years, multimodality therapy based on operation 
for stage 栿A NSCLC has received more and more attention. 
Radiotherapy before operation and/or neoadjuvant 
chemotherapy can shrink tumor lesion and create conditions 
for radical surgery, while radiotherapy after operation can 
improve local control rate and chemotherapy can reduce or 
prevent distant metastasis. Based on the results of this study, 
we think that the postoperative adjuvant therapy for stage 
栿A NSCLC after operation shoulders heavy responsibilities 
and there are more controversies. In clinical work, we 
should choose a therapeutic schedule that is suitable for the 
patient according to each patient’s age, lung function, basic 
physical condition and complications. Particularly for the 
selection of sensitive drugs and radiation dose, we will not 
pursue combined application of wide variety of modalities 
to avoid excessive treatment. We will do our best to improve 
the patient’s survival rate and life quality.
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